Academic Vs. Industry-sponsored Trials: A Global Survey on Differences, Similarities, and Future Improvements

Overview

Journal J Glob Health

Specialties Health Services
Public Health

Date 2024 Nov 22

PMID 39575754

Authors

Jean-Marc Hoffmann

Annina Bauer

Regina Grossmann

Affiliations

Soon will be listed here.

Abstract

Background: Clinical research is marked by its multifaceted nature, presenting a multitude of different approaches, designs, and objectives that can complicate the planning, initiation, and conduct of clinical trials. The role and organisation of the sponsor institution are pivotal in this context. We aimed to investigate possible challenges and needs, including their underlying factors, for academia and industry during the set-up and conduct of clinical trials.

Methods: We conducted a cross-sectional survey-based study within an international network of highly qualified academic research institutions (ARIs). The main outcome measures were the regulatory framework for clinical trials, scope and organisation of academic and industry-sponsored trials, funding sources of academic clinical trials, submission and approval process, as well as study conduct of academic vs. industry-sponsored trials.

Results: We surveyed employees of ARIs with extensive experience in phase I-IV clinical trials. All ARIs participated in academic clinical trials and 90% were involved in industry-sponsored trials. Respondents reported that academic trials faced greater challenges in communication with relevant institutional review boards/ethics committees and competent authorities compared to industry-sponsored trials. Additionally, academic trials were found to have significantly less financial support during their conduct. Specific challenges for academia vs. industry included 'insufficient personnel resources' (60% vs. 50%), 'recruitment problems' (60% vs. 78%) and 'lack of knowledge/experience' (35% vs. 11%).

Conclusions: Our findings indicate that industry-sponsored trials encounter fewer issues in set-up, funding, and trial conduct compared to academic trials. Improving collaboration between academic sponsors and ARIs is essential to address these challenges. ARIs provide critical support and guidance for academic researchers, not only in planning and implementing projects, but also in assessing feasibility and securing funding.

References

Rasmussen K, Bero L, Redberg R, Gotzsche P, Lundh A . Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018; 363:k3654. PMC: 6169401. DOI: 10.1136/bmj.k3654. View

Reed C, Camargo Jr C . Recent trends and controversies in industry-sponsored clinical trials. Acad Emerg Med. 1999; 6(8):833-9. DOI: 10.1111/j.1553-2712.1999.tb01217.x. View

Hoffmann J, Bauer A, Grossmann R . The carbon footprint of clinical trials: a global survey on the status quo and current regulatory guidance. BMJ Glob Health. 2023; 8(9). PMC: 10510862. DOI: 10.1136/bmjgh-2023-012754. View

Spies R, Siegfried N, Myers B, Grobbelaar S . Concept and development of an interactive tool for trial recruitment planning and management. Trials. 2021; 22(1):189. PMC: 7936448. DOI: 10.1186/s13063-021-05112-z. View

Suvarna V . Investigator initiated trials (IITs). Perspect Clin Res. 2013; 3(4):119-21. PMC: 3530977. DOI: 10.4103/2229-3485.103591. View

Blumle A, Wollmann K, Bischoff K, Kapp P, Lohner S, Nury E . Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT). BMC Med Res Methodol. 2021; 21(1):182. PMC: 8406615. DOI: 10.1186/s12874-021-01359-x. View

Kassirer J, Angell M . Financial conflicts of interest in biomedical research. N Engl J Med. 1993; 329(8):570-1. DOI: 10.1056/NEJM199308193290810. View

Shiely F, Foley J, Stone A, Cobbe E, Browne S, Murphy E . Managing clinical trials during COVID-19: experience from a clinical research facility. Trials. 2021; 22(1):62. PMC: 7812560. DOI: 10.1186/s13063-020-05004-8. View

Speich B, von Niederhausern B, Blum C, Keiser J, Schur N, Furst T . Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. J Clin Epidemiol. 2018; 96:73-83. DOI: 10.1016/j.jclinepi.2017.12.022. View

10.

Speich B, Gryaznov D, Busse J, Gloy V, Lohner S, Klatte K . Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis. PLoS Med. 2022; 19(4):e1003980. PMC: 9094518. DOI: 10.1371/journal.pmed.1003980. View

11.

Lexchin J, Bero L, Djulbegovic B, Clark O . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003; 326(7400):1167-70. PMC: 156458. DOI: 10.1136/bmj.326.7400.1167. View

12.

von Niederhausern B, Magnin A, Pauli-Magnus C . The impact of clinical trial units on the value of clinical research in Switzerland. Swiss Med Wkly. 2018; 148:w14615. DOI: 10.4414/smw.2018.14615. View

13.

Kasenda B, von Elm E, You J, Blumle A, Tomonaga Y, Saccilotto R . Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol. 2012; 12:131. PMC: 3528626. DOI: 10.1186/1471-2288-12-131. View

14.

Demotes-Mainard J, Kubiak C . A European perspective--the European clinical research infrastructures network. Ann Oncol. 2011; 22 Suppl 7:vii44-vii49. DOI: 10.1093/annonc/mdr425. View

15.

Hoffmann J, Blumle A, Grossmann R, Yau H, Lang B, Bradbury C . Toward a global harmonization of service infrastructure in academic clinical trial units: an international survey. Front Med (Lausanne). 2023; 10:1252352. PMC: 10602721. DOI: 10.3389/fmed.2023.1252352. View

16.

Hoffmann J, Grossmann R, Widmann A . Academic clinical trials: Publication of study results on an international registry-We can do better!. Front Med (Lausanne). 2022; 9:1069933. PMC: 9729766. DOI: 10.3389/fmed.2022.1069933. View

17.

Sharma A, Duc N, Luu Lam Thang T, Nam N, Ng S, Abbas K . A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med. 2021; 36(10):3179-3187. PMC: 8481359. DOI: 10.1007/s11606-021-06737-1. View

18.

Lathyris D, Patsopoulos N, Salanti G, Ioannidis J . Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest. 2010; 40(2):172-82. DOI: 10.1111/j.1365-2362.2009.02240.x. View

19.

Laterre P, Francois B . Strengths and limitations of industry vs. academic randomized controlled trials. Clin Microbiol Infect. 2015; 21(10):906-9. DOI: 10.1016/j.cmi.2015.07.004. View

20.

Bauer A, Eskat A, Ntekim A, Wong C, Eberle D, Hedayati E . How COVID-19 changed clinical research strategies: a global survey. J Int Med Res. 2022; 50(4):3000605221093179. PMC: 9087250. DOI: 10.1177/03000605221093179. View